February 05, 2025
3 min watch
Save
VIDEO: Inotuzumab study for acute lymphoblastic leukemia requires redesign
SAN DIEGO — Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial.
The study was put on hold due to grade 5 events among patients who received inotuzumab (Besponsa, Pfizer) and progressed onto chemotherapy, according to the abstract.
“On the other hand, I do think there are reasons to be encouraged by the study,” Luskin, a member of the adult leukemia program at Dana-Farber Cancer Institute and an associate professor of medicine at Harvard Medical School, said.
Reference:
- DeAngelo DJ, et al. Abstract 308. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Luskin reports no relevant financial disclosures.
Read more about